Preoperative ultra-hypofractionation radiotherapy in extremity/trunk wall soft tissue sarcoma — A meta-analysis of prospective studies.

The neoadjuvant radiotherapy is now standard treatment in soft tissue sarcoma. Using ultra-hypofractionation radiotherapy shorten the treatment time. In the era of COVID pandemic, using less fraction to treat patient is an urgent need. Thus, we aim to use meta-analysis to investigate the clinical efficacy of preoperative stereotactic body radiotherapy. PRISMA guideline was used in this study. PubMed, Cochrane and Embase were used. We include only prospective study. The main endpoint was set as wound complication rate. Other endpoints include R0 resection rate, overall survival, local control, and distant metastasis free survival. Seven studies were included. The pooled wound complication rate is 0.30 (95% CI = 0.26–0.35). The pooled R0 resection rate is 0.87(95%CI: 0.74–0.94). The pooled 2-year overall survival is 0.86 (95%CI: 0.72–0.94). The pooled 2-year local control rate is 0.96(95%CI: 0.89–0.99). The pooled 2-year distant metastasis free survival is 0.60 (95%CI = 0.50–0.70). Neoadjuvant ultra-hypofractionation radiotherapy in soft tissue sarcoma is a feasible and well tolerable treatment. [ABSTRACT FROM AUTHOR]